Potentiation of doxorubicin cytotoxicity by (+)-1,2-bis-(3,5-dioxopiperazinyl-1-yl) propane (ICRF-187) in human leukemic HL-60 cells

Cancer Commun. 1990;2(4):145-9. doi: 10.3727/095535490820874551.

Abstract

The bisdioxopiperazine propane, ICRF-187, has been reported to potentiate doxorubicin cytotoxicity in certain tumor cell lines; however, the mechanism of this interaction is not known. In order to define the mechanism of this interaction, we examined the effects of ICRF-187 on doxorubicin cytotoxicity, free radical formation, and drug accumulation in human leukemia HL-60 cells. Studies show that ICRF-187 synergistically potentiated doxorubicin cytotoxicity in HL-60 cells. This potentiation of doxorubicin cytotoxicity by ICRF-187 appeared to result from enhanced drug dependent free radical formation without effecting doxorubicin uptake in HL-60 cells.

MeSH terms

  • Biological Transport / drug effects
  • Cell Line
  • Cell Survival / drug effects
  • Daunorubicin / metabolism
  • Doxorubicin / pharmacology*
  • Drug Synergism
  • Electron Spin Resonance Spectroscopy
  • Humans
  • Leukemia, Promyelocytic, Acute
  • Piperazines / pharmacology*
  • Razoxane / pharmacology*
  • Stereoisomerism
  • Tumor Cells, Cultured / cytology
  • Tumor Cells, Cultured / drug effects*

Substances

  • Piperazines
  • Razoxane
  • Doxorubicin
  • Daunorubicin